ProQR Therapeutics N.V.
PRQR
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentoā¦ read more
Healthcare
Biotechnology
11 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.72
Price-3.37%
-$0.06
1Y
Price
Market Cap
$181.132m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in EUR.-354.5%
EBITDA Margin-377.6%
Net Profit Margin-425.5%
Free Cash Flow Margin-354.5%
EBITDA Margin-377.6%
Net Profit Margin-425.5%
Free Cash Flow MarginRevenue
$13.486m
-17.7%
1y CAGR+84.6%
3y CAGR+105.8%
5y CAGREarnings
-$45.708m
-53.3%
1y CAGR+1.4%
3y CAGR-0.4%
5y CAGREPS
-$0.44
-26.5%
1y CAGR+12.6%
3y CAGR+10.8%
5y CAGRBook Value
$37.637m
$99.137m
Assets$61.500m
Liabilities$13.701m
DebtDebt to Assets
13.8%
-0.4x
Debt to EBITDAFree Cash Flow
-$48.994m
-30.7%
1y CAGR-63.0%
3y CAGR-87.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company